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Abstract 
Review on t(9;22)(p24;q11.2) BCR/JAK2, with 
data on clinics, and the genes involved. 
Keywords 
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t(9;22)(p24;q11.2); BCR; JAK2. 
Identity 
G-banded chromosomes showing t(9;22)(p24;q11.2) 
Clinics and pathology 
Disease 
Atypical chronic myeloid leukemia (CML), 
Myeloproliferative neoplasm, unclassifiable; 
Myelodisplastic/myeloproliferative neoplasm, 
unclassifiable; Acute myeloid leukemia, NOS; B 
lymphoblastic leukaemia/ lymphoma, NOS; Burkitt 
lymphoma.  
The translocation t(9;22)(p24;q11.2) JAK2/BCR  
was found in 11 cases. There were seven patients 
with myeloproliferative disorders [Griesinger et al., 
2005; Lane et al., 2008; Impera et al., 2011; 
Belesso et al., Elnaggar et al., 2012; Xu et al., 2013; 
Scwaab et al., 2014], one patient with AML 
[Cirmena et al., 2008].  
ALL was diagnosed in 2 patients [Tirado et al., 
2010; Cuesta- Dominguez et al., 2012], Burkitt 
lymphoma in one patient [Cook et al., 2004].  
Should be noted, in a case of Burkitt lymphoma that 
the molecular study was not been performed. In one 
patient with ALL, the JAK2/BCR fusion has been 
proved by molecular methods, but in another one 
this fusion was  not established. 
Epidemiology 
Median patient's age was 51 (range 14-84) years. 
Sex ratio was 2 male : 1 female patients. 
Treatment 
Some patients with the myeloproliferative disease 
had a response to hydroxyurea and/or interferon 
alfa and achieved partial or complete remission 
[Griesinger et al., 2005; Impera et al., 2011; Xu et 
al., 2013].  
One patient had a good response to ruxolitinib but 
relapsed after 18 months [Schwaab et al., 2014].   
No patients, who achieved remission of the disease 
after treatment with tyrosine kinase inhibitors 
[Griesinger et al., 2005; Impera et al., 2011; 
Belesso et al., 2013].  
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Note that this is just the hypothetical BCR/JAK2 fusion protein. Numbers are amino acids from start of protein. The fusion protein 
contains the coiled-coiled domain of BCR and the kinase domain (PK1 or JH1) of JAK2. 
 
Allogeneic and autologous hematopoietic stem cell 
transplantation was performed for four and one 
patient, respectively [Cirmena et al., 2008; Tirado 
et al., 2010; Belesso et al., 2013; Scwaab et al., 
2014; Cuesta-Dominguez et al., 2012]. 
Prognosis 
Until recently, the prognosis and therapeutic 
options for patients with BCR/JAK2 fusion genes 
were rather different. The fusion genes are seen in 
cases with an aggressive clinical course with rapid 
progression, usually within the first two years after 
diagnosis [Griesinger et al., 2005; Impera et al., 
2011; Belesso et al., 2013]. In some patients, long-
term survival frequently has been achieved after 
autologous or allogeneic SCT [Tirado et al., 2010; 
Cuesta-Dominguez et al., 2012]. 
Cytogenetics 
Cytogenetics molecular 
FISH with a BCR/ABL1 probe (dual color dual 
fusion) will show a split of the BCR signal but no 
fusion signals and two normal ABL1 signals. FISH 
with a JAK2 probe (break-apart) will display a split 
of one JAK2 signal (one co-localized green/red 
signal corresponding to the regular gene copy, and 
one red signal and one green signal, suggesting a 
breakpoint within the JAK2 locus). 
Additional anomalies 
Six patients had translocation t(9;22)(p24;q11.2) as 
a sole aberration [Griesinger et al., 2005; Cirmena 
et al., 2008; Lane et al., 2008; Tirado et al., 2010; 
Belesso et al., 2013]. In one patient the additional 
chromosomal aberrations, such as 7q deletion and 
trisomy 19 were found at blast crisis [Griesinger et 
al., 2005]. An insertion ins(22;9)(q11;p13p24) was 
found in 1 patient [Xu et al., 2013]. A three-way 
translocation with the participation of chromosomes 
9, 22 and 18 was observed in 2 cases [Impera et al., 
2011; Schwaab et al, 2014]. In a case of atypical 
Burkitt lymphoma, the translocation 
t(9;22)(p24;q11.2) was accompanied by 
t(8;14)(q24;q32) [Cook et al., 2004]. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
The chimeric transcripts display the fusion of the 
first exon of BCR to exon 19 or exon 17 or exon 15 
of JAK2, respectively [Xu et al., 2013; Scwaab et 
al., 2014; Cuesta-Dominguez et al., 2012; Elnaggar 
et al., 2012; Impera et al., 2011]. Another variant, 
with fusion of BCR exon 14 to JAK2 exon 11, has 
been reported in one patient with acute myeloid 
leukemia [Cirmena et al., 2008]. 
Only the BCR/JAK2 fusion transcript was detected. 
The reciprocal JAK2-BCR fusion transcript could 
not be amplified. 
 
Nucleotide and amino acid sequence across the BCR/JAK2 
fusion breakpoint. 
Detection 
The fusion transcript can be detected by RT-PCR 
using the 5' BCR sense primer: 5'-
cagaactcgcaacagtccttc-3'(bp 1602-1622) and the 3' 
JAK2 antisense primer: 5'tcataccggcacatctccacac-3' 
(bp 3100-3081). A PCR product of 300 bp should 
be expected. Please note that since only one case is 
known, the breakpoints may vary slightly in future 
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cases. This might necessitate the design of different 
primers. 
Fusion protein 
Note 
The fusion protein was not detected on Western 
blots. 
Description 
The BCR/JAK2 protein contains the BCR coiled-
coil domain fused to the JH1-tyrosine-kinase 
domain of JAK2. 
Oncogenesis 
It has been demonstrated by preclinical studies that 
the kinase domain of JAK2 is activated through 
oligomerization mediated by the coiled-coil domain 
of BCR, as occurred in the constitutive activation of 
BCR/ABL. The BCR/JAK2 induces STAT5 
activation and elicits BCRxL gene expression. 
These factors promote tumorigenic properties and 
lead to increased cell survival [Cuesta-Dominguez 
et al., 2012].  
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